As new treatments extend survival, the threat of SREs increases
- Median progression-free survival (PFS) for patients with advanced renal cell carcinoma treated with sunitinib is 11.8 months (median survival not yet reported)4
- Without treatment, the time to first SRE in patients with advanced renal cell carcinoma is less than 2.5 months2
Median time to first SRE vs PFS in advanced renal cell carcinoma2,4
PAGE
1 2 |